

BIBLIOGRAPHIE

1. Karnak I, Senocak ME, Ciftci AO, et al. Inflammatory myofibroblastic tumor in children: diagnosis and treatment.
J Pediatr Surg. 2001;36:908-912.
2. N. Sirvent et al. : Tumeurs myofibroblastiques inflammatoires.
Ann. Pathol. 2002;22 :453-60.
3. Chun YS, Wang L, Nascimento AG, et al. Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis.
Pediatr Blood Cancer. 2005;45:796-801.
4. Coffin CM, Hornick JL, Fletcher CDM. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.
Am J Surg Pathol. 2007;31:509-520.
5. Gleason BC, Hornick JL. Inflammatory Myofibroblastic tumours: where are we now?
J Clin Pathol. 2008;61:428-437.
6. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
N Engl J Med. 2010;363:1727-1733.
7. R. Alaggio and Al : Inflammatory Myofibroblastic Tumors in Childhood.
Cancer 2010 : 216-226.
8. Ou SHI. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
Drug Des Devel Ther. 2011;5:471-485.
9. Marie-Cardine A, Berrebi D, Orbach D. Guidelines for management of localized inflammatory myofibroblastic tumours in children.
Bull Cancer. 2011;98:209-216.
10. Tao Y-L, Wang Z-J, Han J-G, et al. Inflammatory myofibroblastic tumor successfully treated with chemotherapy and nonsteroidals: a case report.
World J Gastroenterol. 2012;18: 7100-7103.
11. E. Ardini and A. Galvani ; ALK inhibitors pharmaceutical perspectives frontiers in oncology.
February 2012; art 17:1-8.
12. Coffin CM, Fletcher JA. Inflammatory Myofibroblastic Tumour In: WHO Classification of Tumours of Soft Tissue and Bone.
Lyon: IARC Press; 2013:83-84.
13. Bardelli, K. Pantel : Liquid biopsies, what we do not know (yet)?
Cancer Cell perspective: 31
February 13;2017:172-179
14. Gurzu S, Bara T, Jung I. Inflammatory myofibroblastic tumor of the colon.
J Clin Oncol. 2013;31:e155-e158.
15. Mehta B, Mascarenhas L, Zhou S, et al. Inflammatory myofibroblastic tumors in childhood.
Pediatr Hematol Oncol. 2013;30:640-645.
16. Mosse ´ YP, Lim MS, Voss SD, et al. Safety and activity of Crizotinib for paediatric patients with

BIBLIOGRAPHIE

refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Lancet Oncol. 2013;14: 472-480.

17. Solomon BJ, Mok T, Kim D-W, et al. First-line Crizotinib versus chemotherapy in ALK-positive lung cancer.
N Engl J Med. 2014;371:2167-2177.

18. Jacob SV, Reith JD, Kojima AY, et al. An unusual case of systemic inflammatory myofibroblastic tumor with successful treatment with ALK-inhibitor.
Case Rep Pathol. 2014:470340.

19. Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer.
N Engl J Med. 2014; 370:1189-1197.

20. Gaudichon et al .Complete and Repeated Response of a Metastatic ALK rearranged Inflammatory Myofibroblastic Tumor to Crizotinib In a Teenage Girl .
J Pediatr Hematol Oncol; 2016

21. E. Karampini, F. Mc Caugan :
Circulating DNA in solide organ cancers - analysis and clinical applications.
Q/M International Journal of Medicine; 2016:2023-2027.